Shattuck Labs, Inc. (STTK) Balance Sheet

The jump in total assets from $102.1M to $220.7M between Q1 and Q2 2026, driven primarily by a $27.9M increase in cash despite a minimal PPE base, suggests a significant equity financing event. However, the deeply negative retained earnings balance, which expanded by $15.1M in the quarter, indicates the company is still far from self-sustaining operations. This creates a balance sheet that is technically liquid but structurally dependent on external capital to fund ongoing R&D losses.

The near-zero debt load and long-term decline in absolute debt from $4.0M to $2.7M over the past ten quarters reflects a deliberate strategy to avoid leverage while consuming cash reserves. This is typical for pre-revenue biotechs, but it also implies that future capital raises, if needed, will likely be dilutive equity offerings rather than debt, preserving any remaining covenant headroom. The current ratio of 27.59, while extreme, is a byproduct of this all-equity funding model.

The $27.1M cash consumption in a single quarter, occurring even after what appears to be a major equity infusion, is a critical red flag. This burn rate, if sustained, would reduce the current $63.3M cash balance to near-zero within approximately six to seven quarters without further financing. The extremely high current ratio of 27.59 is misleading; it measures a surplus of current assets against minimal liabilities but does not account for the rapid, ongoing consumption of those assets.

The equity structure reveals that the book value is derived from shareholder contributions (common stock and additional paid-in capital) rather than earned value. The $460.4M accumulated deficit dwarfs the total equity figure, meaning shareholders have absorbed massive losses with no operating profitability to show for it. This dynamic forces the company into a perpetual reliance on capital markets, where future equity raises will occur from a position of severe historical value erosion.

The continuous decline in net PPE, with no material capital expenditures evident in the cash flow data, suggests the company is depreciating existing assets without reinvestment. This lack of physical infrastructure investment aligns with a pure-play drug development model but offers no collateralizable asset base. The entire enterprise value proposition is therefore tied to the success or failure of its pipeline, as there are no hard assets to fall back on.